Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, according to a study published online Sept. 7 in Cancer.
Response to neoadjuvant chemo for breast cancer varies by sex
Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, according to a study published online Sept. 7 in Cancer.